Deletion of Ptprd and Cdkn2a cooperate to accelerate tumorigenesis

Area of Science:

• Oncology
• Cancer Biology
• Genetics

Background:

• Protein tyrosine phosphatase receptor type D (PTPRD) is frequently inactivated in human cancers.
• The role of PTPRD loss in promoting in vivo tumorigenesis remains largely unknown.
• PTPRD and CDKN2A are located on chromosome 9p and are often co-deleted in cancers.

Purpose of the Study:

• To investigate whether PTPRD inactivation promotes tumorigenesis in vivo.
• To determine if co-deletion of PTPRD and CDKN2A cooperates in cancer development.
• To explore the potential haploinsufficiency of PTPRD as a tumor suppressor.

Main Methods:

• Utilized a mouse model to study the in vivo effects of PTPRD and CDKN2A co-deletion.
• Assessed the impact of heterozygous and homozygous loss of Ptprd on tumorigenesis.
• Analyzed changes in tumor spectrum and incidence, including lymphomas.

Main Results:

• Co-deletion of mouse Ptprd and Cdkn2a significantly accelerated tumorigenesis.
• Heterozygous loss of Ptprd was sufficient to promote tumor development, indicating haploinsufficiency.
• Loss of Ptprd altered the tumor spectrum in mice, leading to an increased frequency of lymphomas.

Conclusions:

• PTPRD functions as a tumor suppressor gene.
• PTPRD loss can promote tumorigenesis, especially in conjunction with CDKN2A loss.
• PTPRD is a potential tumor suppressor that exhibits haploinsufficiency in cancer development.